Expression of vascular endothelial growth factor and its receptor Flk-1/KDR in benign and malignant breast neoplasms.
- Author:
Ying-jia LI
1
;
Ge WEN
;
Qian WANG
Author Information
- Publication Type:Journal Article
- MeSH: Breast Neoplasms; blood supply; metabolism; Carcinoma, Ductal, Breast; blood supply; metabolism; Female; Humans; Neovascularization, Pathologic; metabolism; Vascular Endothelial Growth Factor A; genetics; metabolism; Vascular Endothelial Growth Factor Receptor-2; metabolism
- From: Journal of Southern Medical University 2009;29(1):70-74
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the differences in the expression of angiogenesis-related molecules between benign and malignant breast neoplasms.
METHODSThirty breast cancer patients (33 foci) and 30 with benign breast neoplasms (34 foci) were examined for CD34, vascular endothelial growth factor (VEGF) and Flk-1/KDR expressions using immunohistochemistry.
RESULTSIn patients with breast cancer, the microvessels densely distributed around the cancer nest. The microvessel density (MVD) in the cancer patients was significantly higher than that in patients with benign tumors (34.48+/-8.34 vs 18.65+/-4.69, P<0.05). In the breast cancer patients, strong VEGF expression was found in the epithelial cells and vascular endothelial cells around the breast carcinoma, and Flk-1/KDR was also strongly expressed in the vascular endothelial cells. The expressions of VEGF and Flk-1/KDR were hardly detectable in the benign tumors.
CONCLUSIONVEGF is an important regulatory factor in promoting breast tumor angiogenesis.
